The Next Wave of ASX Breakouts: Here are 7 Stocks Best Positioned to Follow the Leaders

Everyone is looking for the next wave of ASX breakouts because they happen in every market cycle. Investors still look back at those stories as proof that the ASX can produce globally relevant companies when the right combination of technology, timing, and execution comes together. Companies like Xero, Brainchip and Liontown.

But often, the best companies in their market are ‘second movers’. Remember that before Facebook there was MySpace, and before Google there was Yahoo.

In this article, we look at 7 ASX breakout stories and the most credible successors. We acknowledge some will disagree with our choices, but we think the ones we chose have a structural advantage that sets them apart. They’re not too early, too narrow, or too dependent on a single binary event. But they do have scale, traction, or a platform that can compound. They have the structural characteristics that defined the original success stories they are compared to.

Without any further ado…here are our picks.

7 Stocks Best Positioned to Be the Next ASX Breakouts

1. Arovella Therapeutics (ALA): The Next Mesoblast

Mesoblast’s rise was built on a platform technology with global relevance, a pipeline of high‑value indications, and the ability to attract offshore interest. The company became a symbol of what an Australian biotech could achieve when it combined scientific ambition with commercial discipline. If the question is who can repeat that success, Arovella Therapeutics is the most compelling candidate.

Arovella’s CAR‑iNKT platform sits at the intersection of two powerful global trends: allogeneic cell therapy and next‑generation immuno‑oncology. The company’s approach uses invariant natural killer T cells, which offer advantages in tumour infiltration, persistence, and off‑the‑shelf manufacturing. The preclinical data has been strong, and the platform has the potential to generate multiple therapeutic constructs across oncology.

The reason Arovella stands out is that global capital is flowing into cell therapy, not MSCs or legacy regenerative medicine. Investors want scalable, next‑generation platforms with asymmetric upside. Arovella fits that profile. It is early, but the upside is meaningful if the first human data reads out positively. The company also has a cleaner narrative than many ASX biotechs. It is not trying to be everything to everyone; it is building a focused, high‑value platform in a field where M&A activity remains strong.

Cynata and Orthocell are often mentioned as potential successors, but they fall short for different reasons. Cynata has credible science and late‑stage programs, but the MSC field has lost momentum globally. Orthocell has commercial traction, but its addressable market is narrower. Arovella is the one with the combination of platform potential, global relevance, and rerating capacity that defined Mesoblast’s peak period.

2. Delta Lithium (ASX:DLI): The Next Liontown

Liontown’s success came from scale, grade, and a clear development runway that was realised in the company turning its deposit into a large operating mine. It was a textbook example of how a junior explorer can become a strategic asset in a global supply chain. Delta Lithium is the closest to repeating that arc.

Delta has a large WA resource with strong geological fundamentals. The company is transitioning from exploration to development, which is where Liontown’s value was ultimately unlocked. The project has the right combination of scale, grade, and strategic relevance to attract interest from downstream players. The company also has strong market sponsorship, which matters in a sector where capital intensity is high.

Wildcat and TG Metals have momentum, but their stories are still discovery‑driven. They may deliver strong returns, but they do not yet have the development clarity that defined Liontown’s rise. Delta is already moving into the phase where strategic interest becomes real. It is the one that looks most like a future producer rather than a speculative discovery story.

3. Pointerra (ASX:3DP): The Next Altium

Altium succeeded because it built a globally relevant niche software product with high margins and deep US penetration. It was a small Australian company that became a global leader in PCB design software. Pointerra is the only ASX microcap with a realistic chance of following that path.

Pointerra’s 3D geospatial data platform is gaining traction with US utilities, defence groups, and infrastructure operators. The economics are attractive, the product is sticky, and the addressable market is global. The company has already demonstrated that it can win enterprise‑scale customers in the US, which is the same pattern Altium followed in its early years.

Vection (ASX:VR1) and Mach7 (ASX:M7T) have strengths, but they are either too services‑heavy or too specialised. Pointerra has the cleanest “global niche software” profile. It is the one that could scale into a globally relevant platform if execution remains disciplined. The company also benefits from a structural tailwind: the digitisation of infrastructure and the increasing use of 3D data in asset management.

Pointerra is not without risk. Execution must improve, and the company needs to demonstrate consistent revenue growth. But the ingredients are there, and the market opportunity is real. It is the closest thing the ASX has to another Altium‑style software breakout.

4. Tyro Payments (ASX:TYR): The Next Xero

Xero’s success was built on network effects, recurring revenue, and a platform that scaled globally. It became a category leader by embedding itself into the workflows of small businesses. Tyro is the only ASX fintech with the structural foundations to repeat that trajectory.

Tyro has a large merchant base, strong transaction‑driven revenue, and a defensible payments infrastructure moat. The business is already at scale, and the economics improve as volume grows. The company has the network effects that matter in payments: once a merchant is integrated, switching costs are high. Tyro also has regulatory positioning that creates barriers to entry.

Dubber and other SaaS names have potential, but none have the same combination of network effects, installed base, and recurring revenue. Tyro is the one that can genuinely compound. It has the structural characteristics that defined Xero’s rise, even if the product category is different.

The challenge for Tyro is execution. The company must continue to improve margins and expand its product suite. It has had outages earlier in the decade that caused a ruckus with customers and investors. But the foundation is strong, and the path to scale is clear.

5. Aroa Biosurgery (ASX:ARX): The Next Nanosonics

Nanosonics became a success because it solved a real clinical problem and built a recurring‑revenue model through consumables. It achieved hospital‑level adoption and created a defensible market position. Aroa Biosurgery is the closest to repeating that outcome.

Aroa has strong US commercial traction, reimbursement pathways, and a growing product suite in wound care and soft‑tissue reconstruction. The company has demonstrated that it can scale revenue in the world’s largest healthcare market. The economics are attractive, and the addressable market is large.

Respiri and Next Science have interesting technology, but they remain earlier stage and more dependent on single‑channel adoption. Aroa is already executing at scale. It has the combination of clinical relevance, commercial traction, and recurring revenue that defined Nanosonics’ rise.

The company’s challenge is to continue expanding its US footprint and to broaden its product suite. But the trajectory is strong, and the market opportunity is meaningful.

6. Archer Materials (ASX:AXE): The Next Brainchip

Brainchip’s breakout was driven by deep‑tech IP, global attention, and a compelling narrative around next‑generation computing. It became a symbol of the ASX’s ability to produce high‑risk, high‑reward technology stories. Archer Materials is the only ASX company with a similar profile.

Archer’s quantum computing and semiconductor IP has attracted global research partnerships. The company is working on technologies with asymmetric upside if they succeed. The narrative is strong, and the market opportunity is enormous. Archer has the same “moonshot” potential that defined Brainchip’s rise.

4DS Memory has been glanced at as a promising stock but has never got off the ground due to repeated setbacks. There were times late last decade where it wouldn’t’ve been unfair to say it was ahead of Weebit Nano, but look where Weebit is now. Archer has the broader platform and the global relevance that investors look for in deep‑tech stories. The company must continue to demonstrate technical progress, but the ingredients for a breakout are there.

7. Caspin Resources (ASX:CPN): The Next Chalice

Chalice’s success came from a genuine tier‑one discovery at Julimar and the ability to scale that discovery into a globally significant resource. It was one of the most important exploration successes in recent ASX history. Of all the companies in adjacent geological terrain trying to hit the jackpot, Caspin Resources is the best positioned to follow that path.

Caspin is operating in adjacent geological terrain, targeting similar nickel‑PGE systems. The company has the same “big‑system potential” that characterised Chalice’s early years. It is a pure exploration story with meaningful upside if the geology delivers.

The challenge is that exploration is inherently uncertain. But if the question is who is best positioned to deliver a Chalice‑style discovery, Caspin is the answer.